1. Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry
- Author
-
Shiboski, Caroline H., Baer, Alan N., Shiboski, Stephen C., Lam, Mi, Challacombe, Stephen, Lanfranchi, Hector E., Schiødt, Morten, Shirlaw, Penelope, Srinivasan, Muthiah, Umehara, Hisanori, Vivino, Frederick B., Akpek, Esen, Bunya, Vatinee, Vollenweider, Cristina F., Greenspan, John S., Daniels, Troy E., Criswell, Lindsey A., Cox, D., Jordan, R., Lee, D., Sack, K., Whitcher, J., Lietman, T., McNamara, N., Wu, A., DeSouza, Y., Drury, D., Do, A., Scott, L., Nespeco, J., Whiteford, J., Margaret, M., Adler, I., Smith, A. C., Bisio, A. M., Gandolfo, M. S., Heidenreich, A. M., Chirife, A. M., Keszler, A., Daverio, S., Kambo, V., Jiang, Y., Xu, D., Su, J., Zhao, Y., Dong, Y., Du, D., Wang, H., Li, Z., Xiao, J., Wu, Q., Zhang, C., Meng, W., Zhang, J., Johansen, S., Hamann, S., Lindegaard, J., Schiødt, Julie, Holm, Helena, Helin, P., Ibsen, P., Manniche, A. M., Kreutzmann, S. P., Masaki, Y., Sakai, T., Sugai, S., Kitagawa, K., Shibata, N., Honjo, M., Kurose, N., Nojima, T., Kawanami, T., Sawaki, T., Fujimoto, K., Kirkham, B., Larkin, G., Odell, E., Morgan, P., Fernandes‐Naglik, L., Varghese‐Jacob, B., Seghal, S., Mishra, R., Massaro‐Giordano, M., Abboud, S. K., Pinto, A., Sia, Y. W., Dow, K., Ingrodi, S., Henderson, W., Gourin, C., Keyes, A., Mascarenhas, J., Das, M., Kumar, A., Joshi, Pallavi, Banushree, R., Kim, U., Babu, B., Ram, A., Kannappan, Saravanan, and Kalyani, N.
- Abstract
To explore changes in the phenotypic features of Sjögren's syndrome (SS), and in SSstatus among participants in the Sjögren's International Collaborative Clinical Alliance (SICCA) registry over a 2–3‐year interval. All participants in the SICCAregistry who were found to have any objective measures of salivary hypofunction, dry eye, focal lymphocytic sialadenitis in minor salivary gland biopsy, or anti‐SSA/SSBantibodies were recalled over a window of 2 to 3 years after their baseline examinations to repeat all clinical examinations and specimen collections to determine whether there was any change in phenotypic features and in SSstatus. As of September 15, 2013, a total of 3,514 participants had enrolled in SICCA, and among 3,310 eligible, 771 presented for a followup visit. Among participants found to have SSusing the 2012 American College of Rheumatology (ACR) classification criteria, 93% again met the criteria after 2 to 3 years, and this proportion was 89% when using the 2016 ACR/European League Against Rheumatism (EULAR) criteria. Among those who did not meet ACRor ACR/EULARcriteria at baseline, 9% and 8%, respectively, had progressed and met them at followup. Those with hypergammaglobulinemia and hypocomplementemia at study entry were, respectively, 4 and 6 times more likely to progress to SSby ACRcriteria than those without these characteristics (95% confidence interval 1.5–10.1 and 1.8–20.4, respectively). While there was stability over a 2–3‐year period of both individual phenotypic features of SSand of SSstatus, hypergammaglobulinemia and hypocomplementemia at study entry were predictive of progression to SS.
- Published
- 2018
- Full Text
- View/download PDF